Trial Profile
A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Triamcinolone (Primary)
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Sponsors Flexion Therapeutics
- 01 Dec 2019 Results of pooled Analysis of three Phase 2/3 Clinical Trials (NCT01487161, NCT02116972, NCT02357459) published in the Pain and Therapy
- 08 Nov 2017 Results of subgroup analysis (n=586) assessing the effectiveness of FX006 in patients with and without baseline inflammation using pooled data from three trials (NCT01487161, NCT02116972 and NCT02357459), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 08 Nov 2017 Results of a meta-analysis of two randomised trials (FX006-2014-006 and FX006-2014-008) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting